Carbasalate calcium

CH4N2O 57-13-6) see Alfuzosin Allantoin Amobarbital Barbital Bromisoval Butalbital Carbasalate calcium Carbromal Cyclopentobarbital Dimethadione Dipyridamole Enoximone Ethotoin Heptabarb Metaxalone Methyclothiazide Orotic acid Paramethadione Pentobarbital Phenacemide Phenetuiide Phenobarbital Phenytoin Proquazone Secbutabarbital Secobarbital Sulfadimethoxine Thalidomide Trimethadione... 

Carbasalate calcium is a platelet aggregation inhibitor. It is a mixture of calcium acetylsalicylate and urea. 

Carbasalate calcium is irritating to the gastric mucosa. Therefore, it cannot be administered in capsules. It is administered as single-dose powders in sachets instead. The powders should be dissolved in a glass of water before ingestion. When carbasalate calcium powders are prepared in a pharmacy, the poor flow properties of the active substance may result in a relatively low uniformity of mass. The poor flow of the powder is probably due to an irregular shape of the carbasalate calcium crystals and perhaps also to a relatively wide size distribution of the raw material. 

Carbasalate calcium is a relatively unstable solid active substance, as it degrades through hydrolysis in the presence of moisture. Upon degradation, salicylic acid and acetic acid are formed. The latter can be smelt in very low quantities. To prevent patients becoming needlessly worried, carbasalate calcium powders should be packaged in lightly ventilating material such as paper. 

Generally this will be about the choice of another chemical form, for example theophylline instead of aminophylline or carbasalate calcium instead of acetylsalicylic acid. It is important to pursue a consistent policy on this, for both the stock preparation as well as the extemporaneous preparation and the policy should be clear and consistent. The prescriber should be consulted in order to explain changes to the prescription and in many Countries should be asked consent. 

---